VivoSeq
Metabolic & Endocrine

NASH - Nonalcoholic Steatohepatitis

3

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

NASH - Nonalcoholic Steatohepatitis is an early-stage landscape with 3 programs across 3 companies. The most active players are Hanmi Pharmaceutical Company Limited, Inventiva Pharma, Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

2 programs

Phase 2I

Inventiva Pharma

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Active, not recruiting2 · 100%

Clinical Trials

Trial Activity

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
Active, not recruiting·IInventiva Pharma·Phase 3·NCT04849728·1,000 enrolled
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Active, not recruiting·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 2·NCT04505436·215 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)